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Melatonin is known for its efficacy in breast cancer treatment. However, the safety profile of melatonin, particularly its 
effect on liver, uterus and ovaries is largely unknown. Here, we explored the safety profile of melatonin using virgin female 
mice of the Swiss albino strain. Further, we investigated whether melatonin can overcome liver, ovaries and uterine 
toxicities which are induced by tamoxifen using N,N-dimethylbenzylamine (DMBA) induced breast cancer mouse model? 
Treatment of tamoxifen after breast cancer induction in mice resulted in reduction of breast masses but severe pathological 
abnormalities like liver steatosis, hyper ovulation, ovarian cysts, uterine glands dilatations and endometriosis were observed 
in treated animals. Whereas, melatonin when used in combination with tamoxifen helped to reduce the mouse mammary 
tumor volume and significantly decreases liver enzymes, steroid hormones and oxidative stress. Melatonin also reverted the 
liver, ovarian and uterus toxicity induced by tamoxifen. The results have demonstrated that tamoxifen when used as 
combination therapy with melatonin serve as an effective anti-breast cancer molecule with minimum liver, ovarian and 
uterus toxicities. 
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Breast cancer is the leading cause of mortality in women 
worldwide, and it is the second most common type of 
cancer
1
. There were 2,261,419 new cases of breast 
cancer reported among the women worldwide in 2020 
which account 11.7% of all the cancers
2
. The hormone 
receptors (estrogen, progesterone, human epidermal 
receptor 2) positive breast cancer accounts almost 70 to 
80% of all breast cancers
3
. The effective therapy which 
could benefit the HR-positive (HR+) breast cancer 
patients is to inhibit the estrogen synthesis. Selective 
estrogen receptor modulators such as tamoxifen or 
aromatase inhibitors are routinely used to treat HR 
positive breast cancer. Estrogen receptor modulators 
especially tamoxifen resulted unwanted side effects and 
toxicities in human breast cancer patients and in breast 
cancer animal models
4
. Thus, research for safe estrogen 
modulators with minimum toxicities is an utmost need 
in modern era to treat breast cancer and to control the 
breast cancer related mortalities in human.  
Melatonin is a hormone produced by the pineal gland 
during the dark hours at night that regulates sleep and 
wakefulness. Melatonin acts as a selective estrogen 
receptor modulator and inhibits transcription of estrogen 
receptor (ER) alpha. Melatonin protects against variety 
of diseases such as diabetes, obesity, gastrointestinal 
disorders, immune disorders, cardiovascular diseases, 
and neurodegenerative diseases
4
 and also implicated in 
the treatment of various hormone dependent cancers
5
. 
Melatonin either alone or in combination with other 
chemotherapies has significantly decreased the tumor 
frequency, lengthened tumor latency, increased tumor-
suppressive effects of used anticancer substance in rat 
mammary carcinogenesis, and reduced tumor volume in 
N,N-Dimethylbenzylamine (DMBA) induced breast 
cancer animal model
6
. Melatonin has been considered as 
a safe choice of drug to treat breast cancer but the data 
regarding the experimental evidence about melatonin 
related toxicities in human patients or animal models 
is very limited. In this study, we investigated the 
comparative efficacy of melatonin and tamoxifen 
against breast cancer and studied the relative level of 
toxicity induced by these two estrogen receptor 
modulators on breast, ovaries, uterus and liver using 
DMBA induced breast cancer animal model.  
Material and Methods 
Chemicals 
N,N-Dimethylbenzylamine DMBA (Product Number 








chemicals Co., St. Louis, MO USA. tamoxifen 
(Nolvadex-D) was purchased from AstraZeneca UK 
Limited and melatonin was purchased from Puritans 
Pride, Inc., Holbrook, USA. 
 
Animals 
Twelve weeks old virgin female mice of Swiss 
albino strain were used for this study. The study was 
approved by the graduate Research Committee of the 
College of Science, Department of Zoology, King 
Saud University (Riyadh, Saudi Arabia). The animals 
were maintained and used following national and 
international Guide lines for the Care and Use of 
Laboratory Animals. 
 
Breast cancer induction 
Forty-five virgin female mice received single doses 
(50 mg/kg) of DMBA following the protocol as 
described previously
7
. The DMBA was injected in the 
fat pad of the last pair of breasts. Five mice were 
randomly sacrificed after 10 days post injection and 
then subjected to histopathological examination to 
confirm the induction of breast cancer. 
 
Experimental design 
The mice were divided into following five 
experimental groups having 10 mice in each group as 
indicated here. Control, oral administration of saline; 
DMBA, 50 mg/kg of DMBA; DMBA + tamoxifen, 
oral administration of (35 mg/kg) tamoxifen after the 
induction of breast cancer; DMBA+ melatonin, oral 
administration of (3 mg/kg) melatonin after the 
induction of breast cancer; and DMBA+ tamoxifen+ 
melatonin, oral administration of (3 mg/kg) melatonin 
and (35 mg/kg) tamoxifen after the induction of breast 
cancer. 
 
Breast, liver, and ovary indices 
At the end of the experimental period, each mouse 
was weighed and their left breasts, livers, and left 
ovaries were removed and weighed. Finally, breast, 
liver, and ovary indices were calculated by dividing 
the breast, liver, and ovary by the body weight and 
then multiplying by 100. At the end of experiment 
mice were subjected to anesthesia then sacrificed. The 
means and SD were calculated by statistical software 
SPSS version 16 (SPSS Inc. Released 2007. SPSS for 
Windows, Version 16.0. Chicago, SPSS Inc) 
 
Biochemical analysis 
Blood samples were collected and drawn into 
centrifuge tubes. The samples were centrifuged at 
1008 g-force to separate the sera and stored at 80 ° C 
until the assay. The serum samples were used for the 
estimation of liver enzymes alanine amino transferase 
(ALT) and aspartate amino transferase (AST), sex 
hormones (estrogen and progesterone). Liver 
homogenate was used for the estimation of MDA, 
GSH, catalase, and NO. 
 
Estimation of Aspartate Amino transferase (AST)  
Aspartate aminotransferase (AST) activity in 
treated mice were calculated using aspartate 
aminotransferase (AST) Activity Assay kit cat# 
MAK055 from Sigma- Aldrich (St. Louis, MO 63103, 
USA) following methods essentially as described
8
. 
Aspartate amino transferase (AST) catalyzes the 
transfer of the amino group from aspartate to 2-
oxoglutarate, forming oxalacetate and glutamate. The 
catalytic concentration is determined from the rate of 
decrease of NADH, measured at 340 nm, by means of 
the malate dehydrogenase (MDH) coupled reaction. 
 
Estimation of Alanine Aminotransferase (ALT) activity 
Alanine aminotransferase (ALT) activity in treated 
mice were calculated using alanine aminotransferase 
(ALT) activity Assay kit cat# MAK052 Sigma 
(Sigma-Aldrich St. Louis, MO 63103, USA) 
following instruction of manufacturer. Alanine amino 
transferase (ALT) catalyzes the transfer of the amino 
group from alanine to 2-oxoglutarate, forming 
pyruvate and glutamate. The catalytic concentration is 
determined from the rate of decrease of NADH, 
measured at 340 nm, by means of the lactate 
dehydrogenase (LDH) coupled reaction. 
 
Estrogen and progesterone 
To estimate the level of estrogen, the competitive 
inhibition enzyme immunoassay technique was 
utilized using 17 beta Estradiol ELISA Kit, cat # 
ab108667 (Abcam, Cambridge, MA, UK) following 
protocol as described by manufacturer.  
Progesterone ELISA was used for the quantitative 
measurement of progesterone in mouse serum using 
Progesterone ELISA kit, Catalog Number SE120102 
Sigma-Aldrich St. Louis, MO 63103, USA. 
 
Estimation of levels of antioxidants and oxidative stress markers 
The liver homogenate of each animal in all groups 




Lipid peroxidation was estimated according to the 
method established by  and as described previously
9
. 
About 1.0 mL of trichloroacetic acid 10% and 1.0 mL  
of thiobarbituric acid 0.67%, was mixed followed  
by heating in a boiling water bath for 30 min.  




The thiobarbituric acid reactive substances were 
determined by the absorbance at 535 nm and expressed 
as the MDA equivalents formed. 
 
Glutathione (GSH) 
GSH was determined chemically in the liver 
homogenate using Ellman’s reagent and essentially 
following the same as described previously
10
. The 
method is based on the reduction of Ellman’s reagent 
5,5-dithiobis (2-nitrobenzoic acid) with GSH to 
produce a yellow compound. The chromogen was 
directly proportional to GSH concentration, and its 
absorbance was measured at 405 nm.  
 
Nitric oxide (NO) 
In an acid medium and in the presence of nitrite, 
the formed nitrous acid diazotizes sulphanilamide, 
which is coupled with N-(1-naphthyl) ethylenediamine. 
The resulting azo dye has a bright reddish-purple 
colour, which was measured at 540 nm.  
 
Antioxidant enzyme catalase (CAT) 
Catalase reacts with a known quantity of H2O2. The 
reaction was stopped after exactly 1.0 min with a 
catalase inhibitor. In the presence of horseradish 
peroxidase, the remaining H2O2 reacts with  
3,5-dichloro-2-hydroxybenzene sulfonic acid and  
4-aminophenazone to form a chromophore with a 
color intensity inversely proportional to the amount of 
catalase in the original sample (measured at 240 nm).  
 
Histological examination 
The breast pieces of the liver, ovary, and uterus were 
collected and fixed in 10% neutral buffered formalin. 
Following fixation, the specimens were dehydrated in an 
ascending series of alcohols, embedded in wax, and then 
sectioned to a 5 μm thickness. The sections were stained 
with hematoxylin and eosin and Masson’s trichrome 
following standard protocol. 
 
Statistical analysis  
One-way analysis ANOVA and the statistical 
comparisons among the groups were completed with 
Duncan’s test using a statistical package program (SPSS 
version 16.0) to determine the data mean ± Standard 
deviation (SD). P values ≤0.05 was considered significant.  
 
Results 
The organ indexes of treated mice and control 
group has been shown in Table 1. The mice group 
injected with DMBA showed significant increase in 
breast organ index. The organ index of the group 
injected with DMBA and treated with melatonin 
showed significant increase in breast index as 
compared to control group, and also significant 
decrease in breast index as compared to mice group 
injected with DMBA alone. The mice group injected 
with DMBA and received combined doses of 
tamoxifen and melatonin showed significant decrease 
in breast index and insignificant decrease in liver and 
ovary indexes as compared to DMBA alone injected 
mice group.  
The effect of melatonin, DMBA, and melatonin 
combined with tamoxifen on liver enzyme was 
estimated in treated mice group and compared with 
control group. As shown in Table 2, Mice group 
received melatonin displayed insignificant increase of 
ALT and AST levels as compared to control group. 
Whereas, mice group received combined dose of 
melatonin with tamoxifen showed significant increase 
in ALT and AST levels as compared to control group. 
Mice group injected with DMBA showed significant 
increase in ALT and AST enzymes as compared to 
control group. Mice group received combined dose of 
melatonin with tamoxifen after breast cancer induction 
by DMBA injection showed significant increase 
compared to control group and significant decrease 
compared to group injected with DMBA. Melatonin 
exposure did not induce any toxicity in treated mice 






Control 0.29±0.02 6.4±0.3 0.17±0.04 
Melatonin 0.31±0.0 6.3±0.3 0.15±0.09 
Melatonin+Tamoxifen 0.21±0.04 7.1±0.2 0.17±0.04 
DMBA 0.61±0.07a 7.0±0.2 0.19±0.03 
DMBA+Tamoxifen 0.29±0.05b 6.9±0.2 0.20±0.03 
DMBA+Melatonin 0.44±0.04a,b 6.4±0.2 0.19±0.03 
DMBA+Tamoxifen 
+Melatonin 
0.33±0.05b 6.7±0.3 0.18±0.01 
[Data = mean ± standard error of the mean. a significant difference 
between control and experimental groups; and b significant 
difference between DMBA group and experimental groups] 
 
Table 2 — Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels measured in control and treated 
mouse groups 
 ALTu/l ASTu/l 
Control 37±0.1 110±0.3 
Melatonin 40±0.6 112±1.6 
Melatonin + Tamoxifen 51±0.6a 142±1.2a 
DMBA 85±0.8a 244±6a 
DMBA + Tamoxifen 76±0.8a,b 185±0.9a,b 




[Data = mean ± standard error of the mean. a significant difference 
between control and experimental groups; and b significant 
difference between DMBA group and experimental groups] 
 




group, but rescued the liver damage induced by 





The effect of melatonin treatment on sex hormones 
level is shown in Table 3. Estrogen level showed 
significant increase in groups received melatonin as 
compared to control. The group received combined 
doses of melatonin with tamoxifen revealed significant 
decrease compared to control group. Whereas, mice 
injected with DMBA displayed significant increase in 
estrogen level as compared to control group. Moreover, 
mice group received melatonin alone or combined doses 
of melatonin with tamoxifen after induction of breast 
cancer by DMBA showed significant decrease in 
estrogen level as compared with mice group injected 
with DMBA and control group.  
 
Progesterone 
Progesterone level showed insignificant decrease  
in group received melatonin compared to control 
group. While mice group received combined doses of 
melatonin with tamoxifen had no difference compared 
to control group. The mice group injected with 
DMBA revealed significant increase in progesterone 
level as compared to control group. Group received 
combined doses of melatonin with tamoxifen after 
cancer induction by DMBA injection showed 
insignificant increase compared to control group and 





The response of breast cancer inducted animals to 
oxidative stress upon exposure to melatonin or 
combined doses of melatonin and tamoxifen was 
evaluated by measuring the levels of oxidative stress 
enzymes like malondialdehyde (MDA), Glutathione 
(GSH), Catalase (CAT), and nitric oxide (NO), in 
these animals and were compared with control mice 
groups. The data is presented in Table 4. The breast 
cancer control animals (which were not injected with 
DMBA) showed insignificant increase of MDA level 
upon exposure to melatonin as compared to animals 
which were not treated with melatonin, while 
combined treatment of melatonin and tamoxifen 
raised MDA level significantly in breast cancer 
control animals’ groups. The mice group in which 
breast cancer was induced by DMBA showed a 
significant increase in MDA level which was rescued 
by melatonin alone or combined doses of melatonin 
with tamoxifen (Table 4). 
 
Glutathione (GSH)  
As shown in Table 4, melatonin did not alter the 
glutathione level in treated mice group when 
administered alone as compared to control group. The 
glutathione levels were significantly decrease in mice 
groups who received either tamoxifen alone or 
combined doses of melatonin and tamoxifen as 
compared to control group. The mice group in which 
breast cancer was induced with DMBA revealed a 
significant decrease in glutathione levels as compared 
to mice group which were not injected with DMBA. 
The glutathione levels elevated significantly in mice 
group who received melatonin after induction of 
cancer by DMBA as compared to control group 
(without DMBA). An increase in glutathione level has 
also been observed in mice group who received 
combined doses of melatonin and tamoxifen after 
induction of breast cancer by DMBA comparing with 
mice group injected with DMBA but not treated with 
melatonin and tamoxifen.  
 
Catalase (CAT)  
The response of mice group to catalase activity with 
or without cancer induction and treated with melatonin, 
Table 3 — The estimation of estrogen and progesterone among 
control and experimental groups 
 Estrogen pg/mL Progesterone pg/ mL 
Control 63±0.2 0.2±0.07 
Melatonin 46±0.05a 0.1±0.05 
Melatonin + Tamoxifen 45±0.3a 0.2±0.05 
DMBA 103±0.4a 0.8±0.29a 
DMBA + Tamoxifen 58±0.3a,b 0.3±0.24 




[Data = mean ± standard error of the mean. a significant difference 
between control and experimental groups; and b significant 
difference between DMBA group and experimental groups] 
Table 4 — Estimation of MDA, GSH, CAT and NO (mg/g tissue) 
among control and experimental groups 
 MDA GSH CAT NO 
Control 31±0.1 52±0.2 6±0.4 70±0.8 
Melatonin 40±0.1 50±0.1 4.1±0.02 75±1.8 
Melatonin+Tamoxifen 45±0.1a 41±0.2a 3.7±0.3 94±0.9a 
DMBA 67±0.2a 27±0.1a 2±0.2a 109±1a 
DMBA+Tamoxifen 56±0.2a 38±0.1a,b 3.7±0.3 103±0.3a 











[Data = mean ± standard error of the mean. a significant difference 
between control and experimental groups; and b significant 
difference between DMBA group and experimental groups] 




tamoxifen and combined doses of melatonin and 
tamoxifen is presented in Table 4. CAT levels in groups 
of mice received melatonin, tamoxifen and combined 
doses of melatonin and tamoxifen showed insignificant 
decrease as compared to untreated control group. 
Whereas, group injected with DMBA showed 
significant decrease compared to control group. The 
mice groups, received tamoxifen after cancer induction 
revealed insignificant increase in catalase as compared 
to group injected with DMBA. Mice treated with 
melatonin and combined doses of melatonin with 
tamoxifen after induction of breast cancer by DMBA 
showed significant increase to catalase as compared to 
group injected with DMBA alone (Table 4). 
 
Nitric oxide (NO)  
NO levels increased insignificantly in group of 
mice received melatonin as compared to control group 
(Table 4). Whereas, groups received either tamoxifen 
or combined doses of melatonin with tamoxifen 
revealed significant increase in NO levels as 
compared to control group. In addition, the breast 
cancer inducted mice group displayed significant 
increase in NO levels as compared to control group. 
Moreover, mice group treated with tamoxifen after 
cancer induction by DMBA showed insignificant 
decrease in NO levels as compared to group injected 
with DMBA and not treated with tamoxifen. Mice 
groups treated with melatonin after cancer induction 
showed significant decrease in NO levels as compared 
to group injected with DMBA and not treated  
with melatonin. The NO levels were significantly 
decreased in mice group treated with combined doses 
of melatonin and tamoxifen after breast cancer 
induction as compared to control group (Table 4). It 
shows that the NO levels increased significantly in 
DMBA induced breast cancer mice group. 
Histopathology of breast tissue of mice with or without breast 
cancer induction and treated with melatonin and combined 
doses of melatonin and tamoxifen 
The representative micrograph showing the 
histopathology of breast tissue of control mice and 
mice group in which breast cancer were induced by 
DMBA is shown in Fig. 1. Control breast showed 
normal breast tissue of virgin mice, revealed few 
inactive glands with small ducts (Fig. 1 A-C). The 
control mice group (without breast cancer induction) 
treated with melatonin alone showed normal histology 
of breast, having normal adipose connective tissue 
which contained inactive mammary glands and ducts 
(Fig. 1 D-F). Breast sections of mice received 
combined doses of melatonin and tamoxifen had 
normal breast tissue with inactive mammary glands 
and the ducts indulged in adipose tissue (Fig. 1 G-I).  
The histopathology of breast tissue of mice injected 
with DMBA to induce the breast cancer revealed 
multiple foci of tumor nests and ribbons, invasive 
ductal carcinoma of no specific type (NST) appeared 
surrounded mammary glands and ducts and infiltrate 
the adipose tissue (Fig. 1 J-L). High magnification of 
tumor ribbon revealed atypical cells with variation in 
shape and size (tripolar, quadripolar and elongated) 
failed to develop orientation to one another 
(anaplasia), nuclear irregularity and hyperchromatic 
resulted in hyperplasia (Fig. 1L). Other sections 
showed dilated mammary glands and ducts infiltrated 
by fibers and inflammatory cells, in addition to 
appearance of small blood vessel nearby tumor 
referred to angiogenesis process (Fig. 1K).  
Breast section of mice group received melatonin 
after induction of breast cancer have been shown in 
Fig. 1 M-O. The breast tissue showed marked 
reduction of tumor masses, dilated ducts infiltrated by 
some atypical tumor cells with desmoplastic reaction 
 
 
Fig. 1 — Histopathology of breast tissue of mice with or without breast cancer induction and treated with melatonin, and combined doses 
of melatonin and tamoxifen. H&E: Ematoxylin and Eosin stain, M.Tr: Trichrome staining  




as abundant fibrosis was seen (Fig. 1M). High 
magnification revealed penetration of tumor cells  
to the basement membrane of the duct (Fig. 1N).  
The vascular ectasia (appearance of dilatation and 
congestion of blood vessels) has been observed as well 
(Fig. 1O).  
The breast tissue histology of mice in which breast 
cancer was induced with DMBA and subsequently 
treated with combined doses of melatonin and 
tamoxifen (Fig. 1 P-R) showed healthy breast tissue 
with inactive mammary glands and ducts glands 
infiltrated by a few numbers of tumor cells (Fig. 1P), 
leukocytes and debris of degenerated tumor cells  
(Fig. 1Q), high magnification revealed a few numbers 
of atypical and degenerated tumor cells (Fig. 1R). 
 
Histopathology of liver tissue of mice with or without breast 
cancer induction and treated with melatonin, and combined 
doses of melatonin and tamoxifen.  
Control liver section showed normal structure of liver 
consists mainly of center vein surrounded by 
anastomose network of hepatocytes strands, separated 
from each other by blood sinusoids with abundant 
kupffer cells (Fig. 2 A & B). A The histology of  
liver tissue of control mice which were treated with 
melatonin had normal liver architecture with abundant 
kupffer cells (Fig. 2C). Section stained with Massons 
trichrome showed no depositions of collagenous  
fibers (Fig. 2D). The liver tissue from control mice 
which were treated with combined doses of melatonin 
and tamoxifen revealed healthy hepatocytes with active 
of Kupffer cells , except appearance of steatosis (Fig. 
2E). Masson’s trichrome stained section showed 
reduction in collagenous fibers compared to tamoxifen 
group in addition to a few numbers of leukocytes (Fig. 
2F).  
Liver of mice injected with DMBA group displayed 
histopathological alterations manifested by congested 
central veins infiltrated by leukocytic aggregations, other 
veins appeared filled with oedema, some hepatocytes 
looked degenerated (Fig. G).Section stained with 
Masson’s trichrome showed layers of collagenous fibres 
stained blue with inflammatory cells surrounded 
congested vein. Moreover, multiple necrotic foci 
appeared surrounded by collagenous fibers and 
infiltrative cells mixed with erythrocytes due to 
hemorrhage (Fig. 2H).  
The liver tissue of mice group treated with 
melatonin after breast cancer induction displayed less 
pathological signs as compared to untreated group and 
showed fewer micro vesicles of steatosis and a 
smaller number of degenerated hepatocytes (Fig. 2I). 
Liver section stained with Masson’s trichrome 
showed no fibrosis (Fig. 2J). The mice group treated 
with combined doses of melatonin and tamoxifen had 
healthy hepatocytes and central vein with a few 
numbers of inflammatory cells in liver. Moreover, 
activated Kupffer cells were also observed, in 
addition to the presence of some macrophages. The 
collagenous fibers were also fewer as compared to 
untreated group (Fig. 2 I & J).  
 
 
Fig. 2 — Histopathology of liver tissue of mice with or without breast cancer induction and treated with melatonin, and combined doses 
of melatonin and tamoxifen. H&E: Ematoxylin and Eosin stain, M.Tr: Trichrome staining 




Histopathology of ovary of mice treated with melatonin, and 
combined doses of melatonin and tamoxifen 
Control ovary showed small almond shaped structure 
of normal ovary, that has a cortex which is where 
ovarian follicles can be formed and a highly vascular 
medulla with coiled arteries called helicrine arteries 
(Fig:.3). The ovary cortex contains primordial follicles 
around the edge (Fig. 3A), there are fewer follicles in 
different stages of development as primary follicle, 
antral follicle and corpus luteum (Fig. 3B). Microscopic 
examination of ovary section of control mice group 
(without breast cancer induction) which were treated 
with melatonin revealed healthy ovary having of ovarian 
follicles at different developmental stages (Fig. 3C), 
primordial, primary follicles) and antral follicles (Fig. 
3D). The control mice group (without breast cancer 
induction) treated with combined doses of melatonin and 
tamoxifen had healthy ovaries (Fig. 3 E & G)) 
The histology of ovaries of mice group in which 
breast cancer was induced by DMBA had normal and 
healthy ovary with multiple ovarian follicles (Fig. 
3G)), and without fibrosis (Fig. 3 H). The mice group 
which were treated with melatonin after breast cancer 
induction had healthy ovaries, having ovarian follicles 
at different developmental stages, especially primary 
and antral follicles (Fig. 3 I & J). Moreover, the mice 
group which were treated with combined doses of 
melatonin and tamoxifen after breast cancer induction 
revealed normal number of follicles in different 
stages, and normal vascularectasia (Fig. 3 K & L). 
Histopathology of uterus of mice with or without breast 
cancer induction and treated with melatonin, and combined 
doses of melatonin and tamoxifen.  
Control uterus section (without cancer induction) 
showed normal architecture, consisting mainly 
endometrium and myometrium. Endometrium is lined 
with columnar ciliated and secretory epithelia. Stroma  
of the endometrium contains primarily non  
bundled collagen fibers, uterine glands penetrate the full 
thickness of endometrium. Myometrium displays the 
thickest tunic of the uterus, it contains interwoven layers 
of smooth muscle fibers separated by connective tissue 
containing venous plexus and lymphatics (Fig. 4 A & B) 
Organ histology of uterus sections of un-induced 
breast cancer mice group which were treated with 
melatonin showed healthy uterine sections manifested 
by normal endometrium, uterine glands and myometrium 
(Fig. 4C). Section stained with Masson’s trichrome 
showed diffuse mucin secretion non-bundled collagenous 
fibers that stained blue (Fig. 4D). The control mice which 
were treated with combined doses of melatonin and 
tamoxifen displayed wide dilatation of uterine glands in 
endometrium with hypersecretion (Fig. 4 E & F) 
The histology of uterus of breast cancer induced mice 
group revealed healthy uterus with normal endometrium 
and myometrium (Fig. 4G). Uterus endometrium looked 
blue due to secretions of mucin (Fig. 4H). Uterus section 
of the mice group in which breast cancer was induced 
and then treated with melatonin, showed healthy uterus 
with limited dilatation of uterine glands in endometrium 
 
 
Fig. 3 — Histopathology of ovary of mice with or without breast cancer induction and treated with melatonin, and combined doses of 
melatonin and tamoxifen. H&E: Ematoxylin and Eosin stain, M.Tr: Trichrome staining  




and normal myometrium (Fig. 4 I & J). The histology of 
uterus section in DMBA induced breast cancer mice 
which were treated with combined doses of melatonin 
and tamoxifen showed healthy uterus structure with normal 
endometrium, myometrium and without endometriosis 
or dilatation of uterine glands (Fig. 4 K & L).  
 
Tamoxifen induced hepatotoxicity in treated mice group 
The tamoxifen induced hepatotoxicity in mice group 
in which breast cancer was induced by DMBA 
injection and treated with tamoxifen (Fig. 5H). The 
liver of treated mice had dilated vein congested with 
edema (E) and kupffer cell (arrows) microvesicles (red 
arrows). The hepatotoxicity has not been noticed in the 
mice group in which breast cancer was induced and 
subsequently treated with melatonin and the liver 
histology showed that the mice had healthy liver with 
central vein (CV) and micro vesicles (arrows) (Fig. 5I).   
 
Discussion 
Estrogens and estrogen receptors (ERs) play very 
important role in breast cancer progression 
11
. The 
activation of ERs via estrogen results mammary cell 
 
 
Fig. 4 — Histopathology of uterus of mice with or without breast cancer induction and treated with melatonin, and combined doses of 




Fig. 5 — Histopathology of liver, ovary, and uterus showing comparative efficacy and toxicities of melatonin and tamoxifen in control 
and DMBA induced breast cancer in mouse.  
 




proliferation in healthy mammary gland. However, 
altered ER signaling is associated with abnormal cell 
proliferation as well as the initiation and progression of 
breast cancer
12,13
. Estrogen activates transcription of 
estrogen responsive genes by binding to ER-α, and 
ER-β and thus accelerate tumor cell proliferation
14
. 
The estrogen or progesterone modulation has been 
found in majority of breast cancer in women and 
hence inhibition of estrogen synthesis by using 
selective estrogen receptor modulators (SERMs) have 
somehow benefited the patients in past. Tamoxifen is 
one of the well-known SERM and has shown 
promising results in clinical trials
15
. However, a 
number of studies (our unpublished results)
16
; have 
reported tamoxifen-related toxicities in breast cancer 
patients and animal models, such as hepatocellular 
cancer in rats  risk of endometrial cancer in 
experimental models and in human patients
17-19
. The 
development of resistance against tamoxifen has also 
been seen in some breast cancer patients
20
, which 
demands switching to other SERMs as safe and an 
effective alternative to treat breast cancer
21
.  
Melatonin (N-acetyl-5-methoxy tryptamine) is a 
naturally occurring derivative of the amino acid 
tryptophan and was first isolated from bovine pineal 
gland. Melatonin is well-known regulator for the 
control of the sleep/wake cycle, as well as for 





 has also been attributed 
to melatonin. Melatonin is also involved in preventing 
tumor initiation, promotion, and progression 
29-30
. 
Melatonin is a known inhibitor of estrogen and 
gonadotrophin production  and it is postulated that a 
decrease in melatonin levels might stimulate the 
growth and development of breast cancer in humans. 
Moreover, the impaired melatonin secretion has been 
observed in breast, endometrial, and colorectal cancer 
patients 30 which support the hypothesis of potential 
involvement of pineal gland and its secretion 
“melatonin” in breast cancer progression. Animal 
studies have shown that melatonin attenuates the 
incidence of experimentally induced breast cancers
32-
35
, but there are very few studies which have studied 
the comparative toxicities between melatonin and 
tamoxifen in animals models, hence, in the present 
study we tried to find out the efficacy of melatonin 
over tamoxifen to curb the experimentally induce 
breast cancer in animal model and also to find out 
which one among these two selective estrogen 
receptor modulators is more safe to use by studying 
the comparative toxicity profile in experimental 
animal model system.  
The experimental data; the organ indexes (Table 1), 
blood biochemistry Tables 2, 3 and 4) and organs 
histology (Fig. 1-4) from this study has indicated that 
melatonin could be better choice as compared to 
tamoxifen to treat breast cancer due to the fact that 
melatonin did not induce toxicities that were typical 
manifestation of tamoxifen. The data presented in 
Table 4, clearly showed that the glutathione level in 
mice treated with melatonin alone after induction of 
breast cancer were significantly higher as compared 
with combined doses of melatonin and tamoxifen  
and also with tamoxifen alone. The present study 
illustrated that the co-administration of melatonin 
with tamoxifen after DMBA-induced breast cancer 
resulted in a reduction in the breast index due to the 
reduction of tumor masses in the breast tissue, 
decreased levels of liver enzymes, and the reduction 
of oxidative stress compared to the breast cancer 
group and the group treated with tamoxifen. Moreover, 
a significant reduction in steroidal hormone levels 
was seen in comparison to the breast cancer group and 
the group treated with tamoxifen. 
The present findings revealed that mice injected 
with DMBA in fat pad of breast showed severe 
pathological signs manifested by dilated mammary 
gland infiltrated by desmoplastic reaction and 
angiogenesis in the breast and a congested central 
vein infiltrated by leukocyte aggregations besides 
degenerated hepatocytes in the liver. Whereas, ovaries 
and uterus of breast cancer induced mice were normal 
and had normal follicular antrum, endometrium and 
myometrium. Tamoxifen helped to reduce the tumour 
mass in the breast tissue of the mice group treated 
with tamoxifen after breast cancer induction, but  
still a dilated mammary gland can easily be visualized 
in the breast. However, mice breast treated  
with melatonin after breast cancer induction showed 
normal inactive mammary glands. Tamoxifen treatment 
after breast cancer induction by DMBA resulted in 
hepatotoxicity represented by dilated vein congested 
with edema and highly activation of kupffer cell. The 
hepatotoxicity has not been noticed in the mice group 
in which breast cancer was induced and subsequently 
Melatonin has been used for preventing and 
treating liver injuries and diseases and it also 
protected the liver damage in experimental animals 
which were exposed to variety of hepato-toxins
36-37
. 
The present study illustrated that the administration of 




melatonin after breast cancer induction resulted in the 
reduction of pathological alterations produced in the 
liver, such as inflammation and fibrosis due to 
DMBA. Melatonin administration after the induction 
of breast cancer displayed a decrease in liver enzymes 
and oxidative stress by reducing the levels of MDA 
and NO, as well as increased levels of GSH and 
catalase, compared to the breast cancer group and the 
group treated with tamoxifen after breast cancer 
induction by DMBA. 
The histology of ovaries of mice group treated with 
tamoxifen after breast cancer induction showed hyper 
ovulation as lot of primary follicles (PF) and multiple 
corpus leutea (arrows) were present (Fig. 5M). The 
melatonin did not induce ovarian toxicity in mice 
group treated with melatonin after breast cancer 
induction. The ovaries showed normal primary 
follicle (PF) and follicle antral (FA) (Fig. 5N). The 
tamoxifen also induced uterus toxicity in mice group 
treated with tamoxifen after breast cancer induction. 
The organ histology showed wide dilatation of uterine 
glands (UG) myometrium (MY) (Fig. 5R), while 
uterus mice treated with melatonin after breast cancer 
induction showed normal structure to endometrium 
(EM) and myometrium (MY) (Fig. 5S). The melatonin 
also ameliorated the tamoxifen associated toxicity. 
The organ histology of breast cancer induced mice 
group which were treated with combined doses of 
tamoxifen and melatonin did not show the toxicities 
when treated with tamoxifen alone (Fig. 5E, J, O  
and T). Moreover, the hepatotoxicity, hyper ovulation 
and endometrium were also observed in tamoxifen 
treated control mice (mice in which breast cancer was 
not induced). The tamoxifen associated toxicities in 
normal mice will be presented somewhere else.  
 
Conclusion 
Treatment of tamoxifen after breast cancer 
induction in mice resulted suppression of tumour, 
however, severe toxicity hepatotoxicity, hyper 
ovulation, ovarian cysts, uterine glands dilatations and 
endometriosis were observed in treated animals. 
Whereas, melatonin when used in combination with 
tamoxifen not only helped to reduce the mouse 
mammary tumour volume but also minimized the 
toxicities. The data from this study and other publish 
literature including the clinical trials indicate that 
melatonin alone or in combination with tamoxifen 
could be a better choice of treatment for estrogen and 
progesterone receptor positive breast cancer.  
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